



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SVOP siRNA (m): sc-153953

BACKGROUND

SVOP (synaptic vesicle 2-related protein) is a 548 amino acid multi-pass synaptic vesicle membrane protein that belongs to the major facilitator superfamily. Like some of its family members, SVOP has been shown to bind nucleotides. Functioning as a transporter-like protein that localizes to neurotransmitter-containing vesicles, SVOP is one of the first proteins expressed in the developing nervous system. While expressed at detectable levels in endocrine cells, SVOP is present in all brain regions, with particularly high levels in large pyramidal neurons of the cerebral cortex. The gene that encodes SVOP contains 67,796 bases and maps to human chromosome 12q24.11. Encoding over 1,100 genes, chromosome 12 comprises approximately 4.5% of the human genome. Chromosome 12 is associated with a variety of diseases and afflictions, including hypochondrogenesis, achondrogenesis, Kniest dysplasia, Noonan syndrome and trisomy 12p, which causes facial developmental defects and seizure disorders.

REFERENCES

- Allen, T.L., Brothman, A.R., Carey, J.C. and Chance, P.F. 1996. Cytogenetic and molecular analysis in trisomy 12p. *Am. J. Med. Genet.* 63: 250-256.
- Delgado Carrasco, J., Casanova Morcillo, A., Zabalza Alvillos, M. and Ayala Garcés, A. 2001. Achondrogenesis type II-hypochondrogenesis: radiological features. *Case report. An. Esp. Pediatr.* 55: 553-557.
- Yokoyama, T., Nakatani, S. and Murakami, A. 2003. A case of Kniest dysplasia with retinal detachment and the mutation analysis. *Am. J. Ophthalmol.* 136: 1186-1188.
- Forzano, F., Lituania, M., Viassolo, A., Superti-Furga, V., Wildhardt, G., Zabel, B. and Faravelli, F. 2007. A familial case of achondrogenesis type II caused by a dominant COL2A1 mutation and "patchy" expression in the mosaic father. *Am. J. Med. Genet. A* 143A: 2815-2820.
- Wainwright, H. and Beighton, P. 2008. Visceral manifestations of hypochondrogenesis. *Virchows Arch.* 453: 203-207.
- Lo, F.S., Luo, J.D., Lee, Y.J., Shu, S.G., Kuo, M.T. and Chiou, C.C. 2009. High resolution melting analysis for mutation detection for PTPN11 gene: applications of this method for diagnosis of Noonan syndrome. *Clin. Chim. Acta* 409: 75-77.
- Benussi, D.G., Costa, P., Zollino, M., Murdolo, M., Petix, V., Carrozzini, M. and Pecile, V. 2009. Trisomy 12p and monosomy 4p: phenotype-genotype correlation. *Genet. Test. Mol. Biomarkers* 13: 199-204.
- Chang, W.P. and Südhof, T.C. 2009. SV2 renders primed synaptic vesicles competent for Ca²⁺-induced exocytosis. *J. Neurosci.* 29: 883-897.
- Yao, J. and Bajjalieh, S.M. 2009. SVOP is a nucleotide binding protein. *PLoS ONE* 4: e5315.

CHROMOSOMAL LOCATION

Genetic locus: Svop (mouse) mapping to 5 F.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

PRODUCT

SVOP siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see SVOP shRNA Plasmid (m): sc-153953-SH and SVOP shRNA (m) Lentiviral Particles: sc-153953-V as alternate gene silencing products.

For independent verification of SVOP (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-153953A, sc-153953B and sc-153953C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

SVOP siRNA (m) is recommended for the inhibition of SVOP expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor SVOP gene expression knockdown using RT-PCR Primer: SVOP (m)-PR: sc-153953-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.